MRK241122P115000
- 13.67
- 0.000.00%
Merck & Co Newsroom
Merck & Co To Go Ex-Dividend On December 16th, 2024 With 0.81 USD Dividend Per Share
Bitcoin Climbs to Fresh High, Market Shifts into Climb | Wall Street Today
Merck Readies New Keytruda Version Ahead of Major Regulatory Headwinds
Incyte Pares Some Losses on Report of Potential Merck Takeover Interest
Express News | Merck Is the Latest Industry Giant to Be Linked to a Takeover Bid for Incyte- Sky News Reporter Mark Kleinman on X
J.P. Morgan Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $145
Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under The Skin Injection At Par With Intravenous Formulation In Untreated Lung Cancer Patients
Merck Raises Quarterly Dividend to 81c Vs. 77c >MRK
Express News | Merck Announces First-Quarter 2025 Dividend
Tuesday Market Falls, SMCI Flies, Big Box Retail Reports Mixed | Live Stock
Merck's Cancer Shot Works. Its Post-Keytruda Plans Are Shaping Up Again. -- Barrons.com
Merck Says Injectable Keytruda Succeeded in Late-stage Trial
Express News | Merck Shares up 1.2% Premarket After Trial Shows Injectable Version of Co's Topselling Cancer Drug Keytruda on Par With IV Form
Merck Says Blockbuster Cancer Drug Met Main Goals in Trial of New Under-the-skin Formulation
Express News | Merck Reports Topline Results From Pivotal Phase 3 MK-3475A-D77 Trial; Says Trial Met Its Dual Primary Pharmacokinetic Endpoints
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
Express News | Merck: Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
Jim Cramer Says Merck & Co., Inc. (MRK) Is 'Just Way Too Hated'
S&P Sees Some Signs of a US Credit Bubble as Spreads Tighten
Monday Market Slow but Steady, Trump Buying Crypto Firm | Wall Street Today